glp-1 receptor agonists in pediatric and adolescent obesity diabetes: a systematic review of efficacy, metabolic effects, and safety Role of GLP-1 Receptor Agonists
Description
Liver and diabetes
Liraglutide in apoE / mice reduced body weight as well as suppressed macrophage-driven atherosclerosis
[DOI] [PubMed] [Google Scholar] 64.Ridker PM, et al
Ruan Y, Jiang S, Gericke A
Liraglutide was approved by the FDA for marketing in the United States in 2010 and officially launched in China in 2011
Anti-inflammatory effects of GLP-1 in patients with COVID-19
